FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including oligonucleotide for use in the treatment of ulcerative colitis in a human subject, a pharmaceutical composition containing the above-mentioned oligonucleotide, and a method for the treatment of ulcerative colitis, including the injection of the above-mentioned oligonucleotide or the pharmaceutical composition. In one embodiment, oligonucleotide contains a sequence 5'-GGAACAGTTCGTCCATGGC-3' (SEQ ID NO: 2), and the subject is injected with individual doses from 200 mg to 300 mg of the specified oligonucleotide at least two time-spaced times, wherein the specified time-spaced injections are carried out at intervals of 3 weeks.
EFFECT: invention expands the arsenal of remedies for the treatment of ulcerative colitis.
24 cl, 4 tbl, 3 ex, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR EVALUATING CLINICAL EFFECTIVENESS IN ULCERATIVE COLITIS | 2012 |
|
RU2504779C1 |
| METHODS OF TREATING CHRONIC POUCH ILEITIS | 2018 |
|
RU2822135C2 |
| METHOD FOR TREATMENT OF PEDIATRIC DISORDERS/DISEASES | 2018 |
|
RU2778567C2 |
| AGENT FOR CELL METABOLIC PROCESS REGULATION | 2011 |
|
RU2487720C1 |
| METHODS OF ADMINISTERING INTEGRIN BETA7 ANTAGONISTS | 2012 |
|
RU2595836C2 |
| METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT | 2013 |
|
RU2649807C2 |
| METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES | 2007 |
|
RU2485945C2 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING COMPLICATIONS OF ULCERATIVE COLITIS IN CLINICAL AGGRAVATION | 2022 |
|
RU2815655C1 |
| METHOD OF TREATING CYTOMEGALOVIRUS INFECTION | 2013 |
|
RU2540474C2 |
| COMBINATION THERAPY WITH C-C CHEMOKINE RECEPTOR 9 (CCR9) INHIBITORS AND α4β7-INTEGRIN BLOCKING ANTIBODIES | 2015 |
|
RU2823984C2 |
